The FDA granted priority review for Datroway based on results from the TROPION-Breast02 Phase III trial.
The trial reported a 43% reduction in disease progression or death and an ORR of 64% versus 30% chemotherapy. Credit: 89stocker/Shutterstock.com.
AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab deruxtecan) to treat metastatic triple-negative breast cancer (TNBC).
The approval allows Datroway to be used as a first-line treatment for adults with unresectable or metastatic TNBC who cannot receive programmed cell death protein 1 (PD-1) or PD-L1 inhibitor therapy. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
